 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
INC Research Holdings, Inc. (INCR) is a contract research organization. The company provides various clinical development services for the biopharmaceutical and medical device industries.
The company offers a range of services focusing on Phase I to Phase IV clinical trials in the areas of central nervous system, oncology, and other complex diseases. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics.
The companys services also comprise strategic and regulatory services, including strategic development services, regulatory consulting and submissions, clinical operations optimization, and pricing and reimbursement planning; and post-approval services, such as specialized support for patient registries, safety surveillance studies, prospective observational studies, health outcome research, patient reported outcomes, Phase IV effectiveness trials, health economics studies and retrospective chart reviews.
Shares have formed a bullish "cup and handle" Yesterday, Bloomberg reported that the company and LabCorp (LH) have held talks regarding a potential deal. People with knowledge of the matter tell Bloomberg that the talks are preliminary and the companies may choose not to move forward with a transaction, the report noted. Weather the report are correct or not, we expect higher share prices for this stock.
52-Weeks Trading Range: $29.03 - $57.11
Entry Point: $50.00
Stop Loss: $47.50
Target Price: $55.00
INCR closed at $44 after the company placed a secondary offering.
